ERR3262561
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- PANCREAS_BETA_CELLS+0.500
- MYC_TARGETS_V1+0.400
- ESTROGEN_RESPONSE_LATE+0.300
- FATTY_ACID_METABOLISM+0.300
- KRAS_SIGNALING_DN+0.300
- ADIPOGENESIS+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- ANDROGEN_RESPONSE+0.100
- APICAL_JUNCTION+0.100
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MITOTIC_SPINDLE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- APOPTOSIS-0.300
- DNA_REPAIR-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- TGF_BETA_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-A5GW-01A-11R-A27Q-07 | — | cohortSQ2 | 0.821 |
| 2 | SRR1368772 | GTEX | — | 0.794 |
| 3 | TCGA-CF-A5UA-01A-11R-A28M-07 | — | — | 0.787 |
| 4 | SRR1415095 | GTEX | — | 0.779 |
| 5 | a9e8b311-dfde-4c34-80a2-5e64f94c596b | — | — | 0.778 |
| 6 | SRR1437306 | GTEX | — | 0.777 |
| 7 | MNG42 | — | — | 0.775 |
| 8 | SRR8943035 | — | — | 0.773 |
| 9 | SRR1318426 | GTEX | — | 0.761 |
| 10 | 63e18642-fcf3-460b-95de-de16428dea6d | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.500 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |